|
|
Antimicrob Agents Chemother. 1996 August; 40(8): 1843–1845. | PMCID: PMC163427 |
In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. J Gnarpe, K Eriksson, and H Gnarpe Department of Clinical Microbiology, Gävle Central Hospital, Sweden. Fourteen isolates of Chlamydia pneumoniae, 12 from clinically ill patients and 2 from subjectively healthy individuals from an area within a 400-km proximity of Gävle, Sweden, and strain IOL-207, originally from the eye of an Iranian child, were tested for susceptibilities to the antibiotics doxycycline and azithromycin. MICs and minimum chlamydiacidal concentrations were found to correlate well with values reported earlier by other investigators. In addition to MIC and minimum chlamydiacidal concentration testing, testing for the viability of C. pneumoniae after exposure to antibiotic concentrations as high as 50 mg/liter was carried out by passaging antibiotic-treated, infected cell cultures four times in the absence of antibiotics. It was found that all Chlamydia strains were viable after four passages, regardless of antibiotic concentration in the cell culture. The Full Text of this article is available as a PDF (155K). These references are in PubMed. This may not be the complete list of references from this article. - Belsheim J, Blomqvist C, Löfberg J, Gnarpe H. Tetracycline influence on leukocyte functions. Acta Otorhinolaryngol Belg. 1983;37(4):635–648. [PubMed]
- Belsheim J, Gnarpe H, Persson S. Tetracyclines and host defense mechanisms: interference with leukocyte chemotaxis. Scand J Infect Dis. 1979;11(2):141–145. [PubMed]
- Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J. 1995 Jun;14(6):471–477. [PubMed]
- Falck G, Heyman L, Gnarpe J, Gnarpe H. Chlamydia pneumoniae and chronic pharyngitis. Scand J Infect Dis. 1995;27(2):179–182. [PubMed]
- Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother. 1987 Dec;31(12):1948–1954. [PubMed]
- Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989 Mar;33(3):277–282. [PubMed]
- Grayston JT. Chlamydia pneumoniae, strain TWAR pneumonia. Annu Rev Med. 1992;43:317–323. [PubMed]
- Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis. 1992 Nov;15(5):757–761. [PubMed]
- Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986 Jul 17;315(3):161–168. [PubMed]
- Hammerschlag MR. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother. 1994 Sep;38(9):1873–1878. [PubMed]
- Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, Smith P, Schachter J. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992 Jan;14(1):178–182. [PubMed]
- Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993 Oct;13(10):1501–1504. [PubMed]
- Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev. 1995 Oct;8(4):451–461. [PubMed]
- Roblin PM, Montalban G, Hammerschlag MR. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother. 1994 Jul;38(7):1588–1589. [PubMed]
- Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, Mänttäri M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992 Feb 15;116(4):273–278. [PubMed]
|
This article has been